Biogen Inc. said Friday a trial of a treatment for a rare brain disorder called progressive supranuclear palsy missed its main goal and that it will discontinue its development. The Cambridge, Mass.-based biotech said the phase 2 trial evaluating gosuranemab in treating the disorder, which causes problems with walking, balance and eye movements, also failed to meet clinical secondary endpoints. The company's Chief Medical Officer Alfred Sandrock Jr., said the results were disappointing. Biogen will continue a phase 2 study called Tango evaluating gosuranemab for mild cognnitive impairment due to Alzheimer's disease or mild AD. Shares were slightly higher premarket but are down 2.5% in 2019, while the S&P 500 has gained 26%.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



More...